TIMELESS Contributes to the Progression of Breast Cancer Through Activation of MYC

Overview

Journal Breast Cancer Res

Specialty Oncology

Date 2017 May 4

PMID 28464854

Citations 27

Authors

Limin Chi

Yujiao Zou

Ling Qin

Weifeng Ma

Yanyan Hao

Yao Tang

Rongcheng Luo

Ziqing Wu

Affiliations

Soon will be listed here.

Abstract

Background: Breast cancer is the most common malignancy and the leading cause of cancer death among women. TIMELESS (TIM), a circadian rhythm regulator, has been recently implicated in the progression of human cancer. However, the role of TIM in the progression of breast cancer has not been well-characterized.

Methods: Immunohistochemistry (IHC) staining was used to examine TIM levels in breast cancer specimens. Mammosphere formation analysis and side population analysis were used to examine the effect of TIM on the self-renewal of breast cancer stem cells. A wound healing assay and a Transwell assay were used to determine the role of TIM in breast cancer cell migration and invasion. A soft agar growth assay in vitro and tumorigenicity in vivo were used to determine the role of TIM in tumorigenicity.

Results: TIM levels in both breast cancer cell lines and tissues were significantly upregulated. Patients with high TIM had poorer prognosis than patients with low TIM. Overexpression of TIM dramatically enhanced, while knockdown of TIM suppressed the self-renewal of cancer stem cells (CSCs), cell invasion and migration abilities of breast cancer cells in vitro. Moreover, overexpression of TIM significantly augmented, while knockdown of TIM reduced the tumorigenicity of breast cancer cells in vivo. Mechanism studies revealed that TIM upregulated the expression and the trans-activity of the well-known oncogene MYC. Inhibition of MYC significantly blocked the effects of TIM on CSC population, cell invasion and anchor-independent cell growth.

Conclusion: TIM plays an important role in promoting breast cancer progression and may represent a novel therapeutic target for breast cancer.

Citing Articles

Circadian genes and non-coding RNAs: interactions and implications in cancer.

Yoon G, Roh J, Jang W, Kim W Anim Cells Syst (Seoul). 2025; 29(1):135-148.

PMID: 39944901 PMC: 11816739. DOI: 10.1080/19768354.2025.2459622.

Combinatorial effects of cannabinoid receptor 1 and 2 agonists on characteristics and proteomic alteration in MDA-MB-231 breast cancer cells.

Chutoe C, Inson I, Krobthong S, Phueakphud N, Khunluck T, Wongtrakoongate P PLoS One. 2024; 19(11):e0312851.

PMID: 39527598 PMC: 11554208. DOI: 10.1371/journal.pone.0312851.

The YTH domain-containing protein family: Emerging players in immunomodulation and tumour immunotherapy targets.

Li F, Zeng C, Liu J, Wang L, Yuan X, Yuan L Clin Transl Med. 2024; 14(8):e1784.

PMID: 39135292 PMC: 11319238. DOI: 10.1002/ctm2.1784.

TIMELESS upregulates PD-L1 expression and exerts an immunosuppressive role in breast cancer.

Dong X, Dai H, Lin Y, Sheng X, Li Y, Wang Y J Transl Med. 2023; 21(1):400.

PMID: 37340461 PMC: 10280842. DOI: 10.1186/s12967-023-04257-6.

The TIMELESS effort for timely DNA replication and protection.

Patel J, Kim H Cell Mol Life Sci. 2023; 80(4):84.

PMID: 36892674 PMC: 9998586. DOI: 10.1007/s00018-023-04738-3.

References

Fu A, Leaderer D, Zheng T, Hoffman A, Stevens R, Zhu Y . Genetic and epigenetic associations of circadian gene TIMELESS and breast cancer risk. Mol Carcinog. 2011; 51(12):923-9. DOI: 10.1002/mc.20862. View

Gerber B, Freund M, Reimer T . Recurrent breast cancer: treatment strategies for maintaining and prolonging good quality of life. Dtsch Arztebl Int. 2010; 107(6):85-91. PMC: 2832109. DOI: 10.3238/arztebl.2010.0085. View

Jang A, Moravcevic K, Saez L, Young M, Sehgal A . Drosophila TIM binds importin α1, and acts as an adapter to transport PER to the nucleus. PLoS Genet. 2015; 11(2):e1004974. PMC: 4335507. DOI: 10.1371/journal.pgen.1004974. View

Cho W, Kang Y, An Y, Tappin I, Hurwitz J, Lee J . Human Tim-Tipin complex affects the biochemical properties of the replicative DNA helicase and DNA polymerases. Proc Natl Acad Sci U S A. 2013; 110(7):2523-7. PMC: 3574903. DOI: 10.1073/pnas.1222494110. View

Mao Y, Fu A, Leaderer D, Zheng T, Chen K, Zhu Y . Potential cancer-related role of circadian gene TIMELESS suggested by expression profiling and in vitro analyses. BMC Cancer. 2013; 13:498. PMC: 3924353. DOI: 10.1186/1471-2407-13-498. View

Sander S, Bullinger L, Klapproth K, Fiedler K, Kestler H, Barth T . MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood. 2008; 112(10):4202-12. DOI: 10.1182/blood-2008-03-147645. View

Koh C, Iwata T, Zheng Q, Bethel C, Yegnasubramanian S, De Marzo A . Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget. 2011; 2(9):669-83. PMC: 3248223. DOI: 10.18632/oncotarget.327. View

Dang C . MYC on the path to cancer. Cell. 2012; 149(1):22-35. PMC: 3345192. DOI: 10.1016/j.cell.2012.03.003. View

Meyer N, Penn L . Reflecting on 25 years with MYC. Nat Rev Cancer. 2008; 8(12):976-90. DOI: 10.1038/nrc2231. View

10.

Elgohary N, Pellegrino R, Neumann O, Elzawahry H, Saber M, Zeeneldin A . Protumorigenic role of Timeless in hepatocellular carcinoma. Int J Oncol. 2014; 46(2):597-606. DOI: 10.3892/ijo.2014.2751. View

11.

Lombardo Y, Faronato M, Filipovic A, Vircillo V, Magnani L, Coombes R . Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells. Breast Cancer Res. 2014; 16(3):R62. PMC: 4095694. DOI: 10.1186/bcr3675. View

12.

Clevers H . The cancer stem cell: premises, promises and challenges. Nat Med. 2011; 17(3):313-9. DOI: 10.1038/nm.2304. View

13.

Dubrovska A, Hartung A, Bouchez L, Walker J, Reddy V, Cho C . CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signalling. Br J Cancer. 2012; 107(1):43-52. PMC: 3389396. DOI: 10.1038/bjc.2012.105. View

14.

Dang C, ODonnell K, Zeller K, Nguyen T, Osthus R, Li F . The c-Myc target gene network. Semin Cancer Biol. 2006; 16(4):253-64. DOI: 10.1016/j.semcancer.2006.07.014. View

15.

Guo B, Feng Y, Zhang R, Xu L, Li M, Kung H . Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer. Mol Cancer. 2011; 10(1):10. PMC: 3038148. DOI: 10.1186/1476-4598-10-10. View

16.

Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C . let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell. 2007; 131(6):1109-23. DOI: 10.1016/j.cell.2007.10.054. View

17.

Singh A, Dalton S . The cell cycle and Myc intersect with mechanisms that regulate pluripotency and reprogramming. Cell Stem Cell. 2009; 5(2):141-9. PMC: 2909475. DOI: 10.1016/j.stem.2009.07.003. View

18.

Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D . miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol. 2010; 12(3):247-56. PMC: 2845545. DOI: 10.1038/ncb2024. View

19.

Guney I, Wu S, Sedivy J . Reduced c-Myc signaling triggers telomere-independent senescence by regulating Bmi-1 and p16(INK4a). Proc Natl Acad Sci U S A. 2006; 103(10):3645-50. PMC: 1450136. DOI: 10.1073/pnas.0600069103. View

20.

Raffo D, Berardi D, Pontiggia O, Todaro L, Bal De Kier Joffe E, Simian M . Tamoxifen selects for breast cancer cells with mammosphere forming capacity and increased growth rate. Breast Cancer Res Treat. 2013; 142(3):537-48. DOI: 10.1007/s10549-013-2760-2. View